683 Capital Management, 683 Capital Partners and Ari Zweiman filed Amendment No. 1 to a Schedule 13G updating their ownership in Reviva Pharmaceuticals Holdings, Inc. They may be deemed to beneficially own warrants to purchase 3,492,500 shares of common stock, all currently exercisable.
Based on 115,058,619 shares of common stock outstanding as of November 11, 2025, plus these warrant shares, their holdings represent about 3.0% of Reviva’s common stock. The filers state this amendment is an exit filing because they no longer own more than five percent and certify the securities are not held to change or influence control of the company.
What ownership level in RVPH does 683 Capital report in this filing?
683 Capital reports beneficial ownership of about 3.0% of Reviva Pharmaceuticals Holdings, Inc. common stock. This percentage is based on 115,058,619 shares outstanding plus 3,492,500 shares issuable from currently exercisable warrants held by the reporting persons.
How many RVPH shares does 683 Capital beneficially own according to the Schedule 13G/A?
The reporting persons may be deemed to beneficially own warrants to purchase 3,492,500 shares of Reviva common stock. These warrants are currently exercisable and are the basis for the 3.0% ownership calculation disclosed in the amended Schedule 13G filing.
Why is this Schedule 13G/A for RVPH described as an exit filing?
The amendment is described as an exit filing because the reporting persons no longer beneficially own more than five percent of Reviva’s outstanding common stock. Their reported ownership is now approximately 3.0%, which falls below the five percent reporting threshold.
What type of RVPH securities are held by the reporting persons in this 13G/A?
The reporting persons hold warrants to purchase 3,492,500 shares of Reviva common stock. These warrants are currently exercisable, and the shares issuable upon exercise are included when calculating their 3.0% beneficial ownership position in the company.
Do the reporting persons aim to influence control of RVPH with these securities?
The reporting persons certify the securities were not acquired and are not held to change or influence control of Reviva. They also state the holdings are not part of any transaction intended to affect control, other than activities related to certain nomination provisions.
Who are the reporting persons in the RVPH Schedule 13G/A amendment?
The reporting persons are 683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman. 683 Capital Management is the investment manager to 683 Capital Partners, and Zweiman is the Managing Member of 683 Capital Management, giving them shared voting and dispositive power.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
REVIVA PHARMACEUTICALS HOLDINGS, INC.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
76152G100
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
76152G100
1
Names of Reporting Persons
683 CAPITAL MANAGEMENT, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,492,500.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,492,500.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,492,500.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.0 %
12
Type of Reporting Person (See Instructions)
IA
Comment for Type of Reporting Person: This Amendment No. 1 constitutes an exit filing for the Reporting Persons (as defined below), as the Reporting Persons no longer beneficially own more than five percent of the outstanding shares of the Issuer.
SCHEDULE 13G
CUSIP No.
76152G100
1
Names of Reporting Persons
683 CAPITAL PARTNERS, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,492,500.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,492,500.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,492,500.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.0 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: This Amendment No. 1 constitutes an exit filing for the Reporting Persons (as defined below), as the Reporting Persons no longer beneficially own more than five percent of the outstanding shares of the Issuer.
SCHEDULE 13G
CUSIP No.
76152G100
1
Names of Reporting Persons
Zweiman Ari
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
3,492,500.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
3,492,500.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
3,492,500.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.0 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: This Amendment No. 1 constitutes an exit filing for the Reporting Persons (as defined below), as the Reporting Persons no longer beneficially own more than five percent of the outstanding shares of the Issuer.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
REVIVA PHARMACEUTICALS HOLDINGS, INC.
(b)
Address of issuer's principal executive offices:
10080 N WOLFE ROAD, SUITE SW3-200, CUPERTINO, CA 95014
Item 2.
(a)
Name of person filing:
683 Capital Management, LLC
683 Capital Partners, LP
Ari Zweiman
Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
(b)
Address or principal business office or, if none, residence:
The principal business address for each of the Reporting Persons is 1700 Broadway, Suite 4200, New York, NY 10019.
(c)
Citizenship:
683 Capital Management, LLC - DELAWARE
683 Capital Partners, LP - DELAWARE
Ari Zweiman - UNITED STATES
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
76152G100
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of December 31, 2025, 683 Capital Partners, LP beneficially owned warrants to purchase 3,492,500 shares of Common Stock which are currently exercisable.
683 Capital Management, LLC, as the investment manager of 683 Capital Partners, LP, may be deemed to have beneficially owned the warrants to purchase 3,492,500 shares of Common Stock beneficially owned by 683 Capital Partners, LP.
Ari Zweiman, as the Managing Member of 683 Capital Management, LLC, may be deemed to have beneficially warrants to purchase 3,492,500 shares of Common Stock beneficially owned by 683 Capital Management, LLC.
The following percentage is based on 115,058,619 shares of Common Stock outstanding as of November 11, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2025, plus 3,492,500 shares of Common Stock issuable upon exercise of currently exercisable warrants held by the Reporting Persons.
As of December 31, 2025, the Reporting Persons may be deemed to have beneficially owned 3,492,500 shares of Common Stock, constituting approximately 3.0% of the outstanding shares of Common Stock.
(b)
Percent of class:
3.0%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Cover Pages Items 5-9.
(ii) Shared power to vote or to direct the vote:
See Cover Pages Items 5-9.
(iii) Sole power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
(iv) Shared power to dispose or to direct the disposition of:
See Cover Pages Items 5-9.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See Exhibit 99.1 to Schedule 13G filed on September 29, 2025.
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.